Abstract: An integrated circuit device includes a first chip and a second chip. The first chip includes a first substrate including a through-via region, a prohibition region, and a device region, the prohibition region surrounding the through-via region in a plan view. The first chip further includes a through-via penetrating the first substrate in the through-via region, and a power gating cell disposed in the prohibition region. The second chip includes a second substrate, and a plurality of circuit blocks configured to receive power and/or signals through the through-via.

Abstract: The present invention provides a pharmaceutical composition for protecting or mitigating radiation against radiation-induced damage, comprising a compound of Formula 1, or a pharmaceutically acceptable salt or solvate thereof. Further, the present invention provides a pharmaceutical composition for preventing or treating pulmonary fibrosis, comprising a compound of Formula 1, or a pharmaceutically acceptable salt or solvate thereof.

Abstract: The present invention relates to benzimidazole derivatives having the general formula I, wherein n is 0 or 1; X1 and X2 are independently, at each occurrence, CR5 or N; Y is C1-C6 alkylene, wherein alkylene is optionally substituted with one to two C1-C3 alkyl groups; R1 is selected from the group consisting of hydrogen, halogen, C1-C6 alkoxy, —NH2, —NHR6, —NR7R8 and —NH—(R9)n—R10, n being 0 or 1; R2 is selected from the group consisting of hydrogen, halogen, C1-C6 alkyl, —NH2, —NHR6, —NR7R8 and —NH—(R9)n—R10; R3 is selected from the group consisting of hydrogen, hydroxyl, OR11, —NR7R8, C1-C6 alkoxy, C1-C6 alkyl, C3-C10 cycloalkyl, C1-C3 haloalkyl, —C(O)NHR11, aryl, heteroaryl and heterocyclyl, wherein each of said cycloalkyl, aryl, heteroaryl and heterocyclyl is optionally and independently substituted with one to four Ra groups; and R4 is selected from the group consisting of —NH2, —N(R12)(V)pR13, —NH(V)p—OR14, —NHC(O)R15, and groups of formula 1a shown below, and their use in the treatment of diseases, in

Abstract: The present invention relates to a composition comprising a Salvia miltiorrhiza or Paeonia lactiflora extract as an active ingredient for prevention or treatment of lipid metabolism disorder and, more particularly, provides a pharmaceutical composition and a health functional food composition, each comprising a Salvia miltiorrhiza extract, a Paeonia lactiflora extract, or an extract from a mixture of Salvia miltiorrhiza and Paeonia lactiflora as an active ingredient for prevention or treatment of lipid metabolism disorder. The composition prevents the differentiation of preadipocyte cells to adipocyte cells, reduces blood triglyceride and cholesterol levels, and effectively suppresses fatty liver and visceral fat formation and as such, can be advantageously used as a pharmaceutical and food composition for prevention, alleviation, or treatment of lipid metabolism disorder.

Abstract: The present invention relates to small molecule compounds and their use in the treatment of bacterial infections, in particular Tuberculosis.

Abstract: The present invention relates to small molecule compounds having the general formula (I): wherein A is a moiety selected from the group consisting of formulae (A) to (K) and their use in the treatment of bacterial infections, in particular Tuberculosis.

Abstract: Disclosed is an electronic device and multitasking interface providing method therefor. The electronic device presents at least a portion of specific content on at least a portion of the display via a window having a size desired by the user, provides a multi-window display according to user input and determines the content to be displayed in each window, and provides an update on specific content via the first window of the multi-window and an application list enabling application switching via the second window.

Abstract: The present invention provides a pharmaceutical composition for inhibiting DNA damage, comprising a GSK3 inhibitor. Further, the present invention provides a pharmaceutical composition for protecting or mitigating radiation against radiation-induced damage, or preventing or treating pulmonary fibrosis, comprising a GSK3 inhibitor.

Abstract: Disclosed is an electronic device and multitasking interface providing method therefor. The electronic device presents at least a portion of specific content on at least a portion of the display via a window having a size desired by the user, provides a multi-window display according to user input and determines the content to be displayed in each window, and provides an update on specific content via the first window of the multi-window and an application list enabling application switching via the second window.

Abstract: A network system is provided. The network system includes: at least one component selected from an energy receiving unit receiving energy and an energy management unit managing the energy receiving unit. The energy receiving unit or the energy management unit receives energy rate related information; an energy usage amount or a usage rate of when the component is controlled on the basis of at least the energy rate related information is less than that of when the component is controlled without the basis of at least energy rate related information; if the energy rate related information is high cost information, a function of one component constituting the energy receiving unit is limited; and an operating time or an output of the energy receiving unit is adjusted in correspondence to the limited function of one component.

Abstract: The present invention relates to benzimidazole derivatives having the general formula I, wherein n is 0 or 1; X1 and X2 are independently, at each occurrence, CR5 or N; Y is C1-C6 alkylene, wherein alkylene is optionally substituted with one to two C1-C3 alkyl groups; R1 is selected from the group consisting of hydrogen, halogen, C1-C6 alkoxy, —NH2, —NHR6, —NR7R8 and —NH—(R9)n—R10, n being 0 or 1; R2 is selected from the group consisting of hydrogen, halogen, C1-C6 alkyl, —NH2, —NHR6, —NR7R8 and —NH—(R9)n—R10; R3 is selected from the group consisting of hydrogen, hydroxyl, OR11, —NR7R8, C1-C6 alkoxy, C1-C6 alkyl, C3- C10 cycloalkyl, C1-C3 haloalkyl, —C(O)NHR11, aryl, heteroaryl and heterocyclyl, wherein each of said cycloalkyl, aryl, heteroaryl and heterocyclyl is optionally and independently substituted with one to four Ra groups; and R4 is selected from the group consisting of —NH2, —N(R12)(V)pR13, —NH(V)p—OR14, —NHC(O)R15, and groups of formula 1a shown below, and their use in the treatment of diseases, in

Abstract: The present invention relates to small molecule compounds having the general formula (I): wherein A is a moiety selected from the group consisting of formulae (A) to (K) and their use in the treatment of bacterial infections, in particular Tuberculosis.

Abstract: The present invention relates to small molecule compounds and their use in the treatment of bacterial infections, in particular Tuberculosis.

Abstract: The present invention refers to: a compound having the general formula (I), wherein n is 0, 1, 2 or; m is 0, 1, 2 or 3; o is 0, 1, 2 or 3; W, X, Y and Z are independently selected from CH, N or N-oxide; A is NR4, C?O, C?S, OP(O)(O), P?O, CH2, or a heteroarly selected from the group consisting of (a), (b), (c), (d), (e), (f), (g); V is C?O, O, S, CH2, or NR5; as well as its use in treating inflammatory diseases such as asthma, COPD, inflammation post infection, arthritis, atherosclerosis, pain and dermatitis.

Abstract: The present invention relates to 4H-pyrido[1,2-a]pyrimidin-4-one compounds and their use in the treatment of bacterial infections, in particular Tuberculosis.

Abstract: The present invention relates to small molecule compounds and their use in the treatment of bacterial infections, in particular Tuberculosis.

Abstract: The present invention relates to 4H-pyrido[1,2-a]pyrimidin-4-one compounds and their use in the treatment of bacterial infections, in particular Tuberculosis.

Abstract: The present invention refers to: a compound having the general formula (I), wherein n is 0, 1, 2 or; m is 0, 1, 2 or 3; o is 0, 1, 2 or 3; W, X, Y and Z are independently selected from CH, N or N-oxide; A is NR4, C?O, C?S, OP(O)(O), P?O, CH2, or a heteroarly selected from the group consisting of (a), (b), (c), (d), (e), (f), (g); V is C?O, O, S, CH2, or NR5; as well as its use in treating inflammatory diseases such as asthma, COPD, inflammation post infection, arthritis, atherosclerosis, pain and dermatitis.

Abstract: A network system is provided. The network system includes: at least one component selected from an energy receiving unit receiving energy and an energy management unit managing the energy receiving unit. The energy receiving unit or the energy management unit receives energy rate related information; an energy usage amount or a usage rate of when the component is controlled on the basis of at least the energy rate related information is less than that of when the component is controlled without the basis of at least energy rate related information; if the energy rate related information is high cost information, a function of one component constituting the energy receiving unit is limited; and an operating time or an output of the energy receiving unit is adjusted in correspondence to the limited function of one component.

Abstract: Provided is a network system. The network system includes a first component performing a preset function, the first component having a first device code and a second component exchanging information with the first component to be communicably connected to the first component, the second component having a second device code. When a command for communicable connection is inputted into the first component or the second component, a connection sequence is generated from the component in which the command is inputted to exchange an IP address and the device code of each of the components between one component generating the connection sequence and the other component receiving the connection sequence.